Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30389775 | 0.78 | TRPC6 (0.44) | PDE4APDE4DPDE4B | |
| SCHEMBL21284444 | 0.71 | TRPC6 (0.70) | — | |
| SCHEMBL3721721 | 0.70 | HPGD (0.58) | KMOPDE4BHPGD | |
| SCHEMBL30902449 | 0.70 | HPGD (0.58) | KMOPDE4BHPGD | |
| SCHEMBL15351087 | 0.69 | CNR2 (0.38) | HPGD | |
| SCHEMBL637014 | 0.69 | FDPS (0.67) | PDE4APDE4DPDE4BHPGD | |
| SCHEMBL24386866 | 0.68 | ALDH1A1 (0.40) | ERN1HPGD | |
| SCHEMBL28604786 | 0.68 | ALDH1A1 (0.40) | ERN1HPGD | |
| SCHEMBL29952643 | 0.68 | ALDH1A1 (0.40) | ERN1HPGD | |
| SCHEMBL29954314 | 0.68 | ALDH1A1 (0.40) | ERN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752499-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | claimed |
| US-11485740-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-01 | — | — | US | claimed |
| EP-3752499-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-11485740-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485740-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC4 | KMO 1290/4885GRM2 4040/4885PDE4A 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.